BioNTech SE (BioNTech SE) Beginning Cash Position : $12,678 Mil (As of Mar. 2024)

View and export this data going back to 2019. Start your Free Trial

What is BioNTech SE Beginning Cash Position?

BioNTech SE's Beginning Cash Position for the quarter that ended in Mar. 2024 was $12,678 Mil.

BioNTech SE's quarterly Beginning Cash Position declined from Sep. 2023 ($15,119 Mil) to Dec. 2023 ($14,717 Mil) and declined from Dec. 2023 ($14,717 Mil) to Mar. 2024 ($12,678 Mil).

BioNTech SE's annual Beginning Cash Position increased from Dec. 2021 ($1,367 Mil) to Dec. 2022 ($1,793 Mil) and increased from Dec. 2022 ($1,793 Mil) to Dec. 2023 ($15,131 Mil).

BioNTech SE Beginning Cash Position Historical Data

The historical data trend for BioNTech SE's Beginning Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BioNTech SE Beginning Cash Position Chart

BioNTech SE Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Beginning Cash Position

Get a 7-Day Free Trial

457.22

631.51

1,367.46

1,793.11

15,130.97

BioNTech SE Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Beginning Cash Position	Get a 7-Day Free Trial															14,855.57	13,156.99	15,119.10	14,717.34	12,677.94

BioNTech SE Beginning Cash Position Calculation

Beginning Cash Position is the cash and equivalents balance at the beginning of the accounting period, as indicated on the Cash Flow statement.

BioNTech SE Beginning Cash Position Related Terms

Thank you for viewing the detailed overview of BioNTech SE's Beginning Cash Position provided by GuruFocus.com. Please click on the following links to see related term pages.

BioNTech SE (BioNTech SE) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » BioNTech SE (NAS:BNTX) » Definitions » Beginning Cash Position

Comparable Companies

Traded in Other Exchanges

BNTX:Mexico 0A3M:UK 22UA:Germany B1NT34:Brazil BNTX:Austria

Address

An der Goldgrube 12, Mainz, RP, DEU, D-55131

Website

https://www.biontech.de

BioNTech is a Germany-based biotechnology company that focuses on developing cancer therapeutics, including individualized immunotherapy, as well as vaccines for infectious diseases, including COVID-19. The company's oncology pipeline contains several classes of drugs, including mRNA-based drugs to encode antigens, neoantigens, cytokines, and antibodies; cell therapies; bispecific antibodies; and small-molecule immunomodulators. BioNTech is partnered with several large pharmaceutical companies, including Roche, Eli Lilly, Pfizer, Sanofi, and Genmab. COVID-19 vaccine Comirnaty is its first commercialized product.